2023年第46届圣安东尼奥乳腺癌研讨会（San Antonio Breast Cancer Symposium，SABCS）将于12月5日至9日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家，是规模最大、最具影响力的乳腺癌研究盛会。
日前，大会公布了本次会议的详细日程及研究题目，150余项中国研究成果入选SABCS。【肿瘤资讯】从官网获得现有资讯，将入选POSTER session 5的中国研究信息整理如下，以飨读者。
PO5-01-04 HER2 Amplification Level and Focal/Broad Region Size as Predictors of Treatment Response in Neoadjuvant Chemotherapy and Anti-HER2 Therapy for HER2-Positive Breast Cancer.
作者：Ning Liao，Guochun Zhang，Xinze Lv，Kai Li，Ting Hou，Zhou Zhang
第一作者单位: Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
PO5-01-05 An Open-label, Single-center Study Assessing the Efficacy of PH-based Regimen as Neoadjuvant Therapy for HER2-positive Early-stage Breast Cancer: Integrating Genomic Features and Functional Imaging.
作者：Ming Chen，Benlong Yang，sun yuyun，Linxiaoxi Ma，song shaoli，Min He，Zhi-Ming Shao，Bingqiu Xiu，Jiong Wu
第一作者单位: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032 China Department of Oncology, Fudan University Shanghai Medical College, Shanghai, 200032 China
PO5-02-08 Prognostic value of serum lipid levels in breast cancer patients who received neoadjuvant chemotherapy: A retrospective exploratory analysis of the prospective cohort.
作者：Xinru Chen，Wenjin Yin，Yingying Zhao，Jinsong Lu
第一作者单位: Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, China (People's Republic)
PO5-02-10 Favorable effect of HER2-low expression on prognosis for breast cancers after neoadjuvant chemotherapy.
作者：Yingying Zhao，Wenjin Yin，Xinru Chen，Jingsong Lu
第一作者单位: Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, Shanghai, China (People's Republic)
PO5-03-05 Rethinking the value of pathologic complete response rate for the survival outcomes of early triple-negative breast cancer treated with neoadjuvant chemotherapy: a systematic review and network meta-analysis.
作者：Xiaoying Qiao，Taobo Hu，Baosheng Liang，Shu Wang
第一作者单位: Peking University People's Hospital, Beijing, China (People's Republic)
PO5-04-01 Inetetamab combined with sirolimus and chemotherapy in HER2 positive metastatic breast cancer patients with abnormal activation of Pi3k/Akt/mTOR pathway after trastuzumab treatment.
作者：Qiao li，Dan Lv，Xiaoying Sun，Mengyuan Wang，Li Cai，Feng Liu，chenghui li，Jiuda Zhao，jing sun，Yehui Shi，Fei Ma
第一作者单位: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China (People's Republic)
PO5-06-11 RPL27A promotes the growth and metastasis of triple negative breast cancer by regulating Ribosome biogenesis.
作者：Weipeng Zhao，jingyi Zhang，ye Zhu，xin Yang，Xichuan Li
第一作者单位: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
PO5-07-02 AI-assisted interpretation of PD-L1 CPS improves the precision medicine in Triple-negative breast cancer.
作者：Jinze Li，Xinran Wang，Yueping Liu
第一作者单位: Department of Pathology, The Fourth Hospital of Hebei Medical University.
PO5-08-10 Breast cancer risk prediction performance of polygenic risk score in Taiwanese female with dense breast: A nested case-control study.
作者：Chih Yean Lum，Chih Chiang Hung，Chi-Cheng Huang ，Tzu-Hung Hsiao，Sin-Hua Moi
第一作者单位: TaiChung Veterans General Hospital, Taichung, Taiwan (Republic of China)
PO5-16-04 Tissue-informed personalized MRD detection assay may outperform tumor-informed fixed panel strategy in Triple Negative Breast Cancer (TNBC).
作者：Shunying Li，Wei Gao，Ning Fu， Wuqiang Cao，Xiaoling Zeng，Xinhua Du， Qiang Liu
第一作者单位：Sun Yat-sen Memorial Hospital, Sun Yat-sen University
PO5-18-09 Anthracycline-free neoadjuvant therapy with nab-paclitaxel and carboplatin in non-luminal breast cancer: a single-arm phase II trial.
作者：Deyue Liu，Li Zhu，Jiayi Wu，Wei Wang，Shuning Ding
第一作者单位: Department of Breast and Thyroid Surgery, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine
PO5-21-05 An Endocrine Resistant-Related Gene Signature Revealing the Tumor Microenvironment to Predict the Prognosis of Hormone Receptor-Positive Breast Cancer Patients.
作者：Xiyu Kang，Jiaxiang Liu ，Xin Wang
第一作者单位: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
PO5-24-10 Clinical significance and immune landscape analyses of the immune related genes based prognostic signature for HER2 positive breast cancer.
作者：Xiaofen Li，Wenfen Fu，Yushuai Yu，Jie Zhang，Chuangui Song
第一作者单位: Fujian Cancer Hospital
SABCS中国之声总览：
Rapid Fire Session: Mini-Oral Presentations、POSTER SPOTLIGHT Session
本文检索了POSTER SESSIONS中第一作者单位为中国单位的研究。如果有任何错误或遗漏，请联系我们进行修改。
排版编辑：肿瘤资讯-张薪媛
苏公网安备 32059002004080号
